Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805159 | 0.85 | HSD17B10 (0.65) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL8867858 | 0.84 | ADRA1A (0.68) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL1046460 | 0.83 | APLNR (0.63) | HSD17B10IDO1ADRA1ATAAR1CA12 | |
| SCHEMBL10526058 | 0.83 | IDO1 (0.61) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL5252421 | 0.83 | IDO1 (0.66) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL20718930 | 0.81 | IDO1 (0.63) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL8491999 | 0.80 | ADRA1A (0.68) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL1055293 | 0.79 | IDO1 (0.61) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL487944 | 0.79 | HSD17B10 (0.62) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL1264360 | 0.79 | HTR2A (0.62) | HSD17B10IDO1ADRA1ATAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | claimed |
| EP-1883402-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-02-06 | — | — | EP | claimed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| EP-0365328-B1 | Pyridine derivatives | ZENECA LTD (GB) | 1996-04-03 | — | — | EP | claimed |
| EP-0497740-B1 | Benzyloxyphenyl derivatives | SANDOZ LTD (CH) | 1994-12-14 | — | — | EP | claimed |
| EP-0497740-A1 | Benzyloxyphenyl derivatives | SANDOZ LTD. (CH) | 1992-08-05 | — | — | EP | claimed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | claimed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | claimed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0497740-B1 | Benzyloxyphenyl derivatives | SANDOZ LTD (CH) | 1994-12-14 | — | — | EP | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| EP-0497740-A1 | Benzyloxyphenyl derivatives | SANDOZ LTD. (CH) | 1992-08-05 | — | — | EP | disclosed |
| US-5053415-A | Antiischemic, antiinflammatory, antiarthritic agents, cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | disclosed |
| EP-0365328-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSD17B10 697/4885IDO1 187/4885ADRA1A 685/4885 |
| US-20080306054-A1 | Pharmaceutical Compounds | HSP90AB1, HSP90AA1, HSP90AB2P | HSD17B10 217/4885IDO1 853/4885ADRA1A 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.